A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline

$277,203P50FY2016NSNIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 39557903 Paper 39372921 Paper 39228745 Paper 38610104 Paper 38183891 Paper 37964373 Paper 36917977 Paper 36857870 Paper 36269086 Paper 35997131 Paper 35981040 Paper 35762106 Paper 35593028 Paper 35592691 Paper 35150470 Paper 34997851 Paper 34854996 Paper 34480363 Paper 34288137 Paper 33938021 Paper 33720852 Paper 33593865 Paper 33505021 Paper 33492664 Paper 33386814 Paper 33108692 Paper 33097764 Paper 33021680 Paper 33002767 Paper 32892355 Paper 32804255 Paper 32741842 Paper 32520435 Paper 32358220 Paper 31996268 Paper 31899072 Paper 31837422 Paper 31660655 Paper 31603904 Paper 31505070 Paper 31392244 Paper 31361367 Paper 31346295 Paper 31127775 Paper 31062392 Paper 31036761 Paper 30953760 Paper 30905591 Paper 30771169 Paper 30657670 Paper 30549331 Paper 30488277 Paper 30473927 Paper 30457571 Paper 30448004 Paper 30337152 Paper 30337151 Paper 30321501 Paper 30306618 Paper 30297518 Paper 30285047 Paper 30234179 Paper 30216541 Paper 30203094 Paper 30169897 Paper 30155787 Paper 29969907 Paper 29929376 Paper 29878075 Paper 29855356 Paper 29743672 Paper 29700597 Paper 29619565 Paper 29604263 Paper 29543342 Paper 29502200 Paper 29500813 Paper 29486463 Paper 29442392 Paper 29400668 Paper 29293269 Paper 29263008 Paper 29209768 Paper 29168904 Paper 29121998 Paper 29076399 Paper 29073330 Paper 29063713 Paper 29039849 Paper 28986467 Paper 28969902 Paper 28922167 Paper 28914737 Paper 28906025 Paper 28900002 Paper 28887905 Paper 28751258 Paper 28719018 Paper 28711192 Paper 28671140

Abstract

Two key obstacles to efficient experimental therapeutics for cognitive impairment (CI) associated with Parkinson's disease (PD) are lack of accurate prediction of which patients are at highest risk for CI in the near term, and heterogeneity in the pathology underlying CI in PD and Parkinson's disease dementia (PDD). Project 1 will address both of these critical issues. The first goal of the project is to improve the ability to predict which patients with PD are at highest risk for developing CI by building a predictive model that combines clinical and biomarker data. The second goal of the project is to better understand potential pathological subtypes of dementia in PDD and Lewy Body Dementia (LBD) by examining patterns of expression of clinical and biomarker features which may reflect different underlying pathology. The specific aims of Project 1 are: 1) to replicate previously-reported candidate biomarkers of CI in a training cohort of LBSD patients; 2) to define relationships among candidate biomarkers in Aim 1 to identify potential pathophysiological subtypes of cognitive impairment in PD and DLB; and 3) to develop a multimodal predictive algorithm for cognitive decline in PD and apply it to an independent test cohort of PD patients. We will accomplish these aims in the context of longitudinal cohort study that uses data already collected in the first funding cycle of the Penn Udall Center along with additional data collected in this cycle. We will use Hierarchical Cluster Analysis and Principal Components Analysis to examine patterns of clinical and biomarker expression. We will use a split-sample approach to developing and testing the predictive algorithm. The products of this study will be a deeper understanding of the inter-relations of clinical and biological features of CI in PD and a practical tool for assessing the risk of developing this disabling complication.

View original record on NIH RePORTER →